Key Points
- CEO sale: KalVista CEO Benjamin Palleiko sold 1,038 shares on Feb. 18 at $15.00 for $15,570, leaving him with 429,667 shares (a 0.24% reduction in his position).
- Stock snapshot: Shares traded at $15.76 mid-day with light volume (113,039 vs. a ~1.04M average), a 1‑year range of $9.23–$19.00 and a market cap of about $796.4 million.
- Analyst view: Consensus rating is "Moderate Buy" (7 Buys, 1 Sell) with a consensus target price of $29.40, and several firms recently raised targets (as high as $37).
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 1,038 shares of the firm's stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $15.00, for a total value of $15,570.00. Following the completion of the transaction, the chief executive officer owned 429,667 shares in the company, valued at approximately $6,445,005. This trade represents a 0.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
KalVista Pharmaceuticals Price Performance
Shares of NASDAQ KALV traded down $0.14 during mid-day trading on Friday, reaching $15.76. The company's stock had a trading volume of 113,039 shares, compared to its average volume of 1,035,148. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.23 and a 1-year high of $19.00. The stock has a market capitalization of $796.42 million, a P/E ratio of -3.99 and a beta of -0.19. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The stock has a 50-day moving average of $15.52 and a two-hundred day moving average of $13.87.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its holdings in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock valued at $46,000 after acquiring an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter worth about $55,000. Wolverine Asset Management LLC acquired a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $57,000. KLP Kapitalforvaltning AS bought a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $63,000. Finally, Truvestments Capital LLC increased its holdings in KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company's stock worth $76,000 after buying an additional 3,360 shares during the last quarter.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on KALV. TD Cowen reaffirmed a "buy" rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. HC Wainwright lifted their price objective on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a "buy" rating in a research note on Friday, January 9th. Needham & Company LLC increased their target price on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a "buy" rating in a research note on Tuesday, January 6th. Citigroup restated a "market outperform" rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.40.
Read Our Latest Stock Report on KALV
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
